← Dashboard
Stock
HAE
HAEMONETICS CORPORATIONHealth CareHealth Care SuppliesLatest close $577 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
3
Exited this quarter
1
Marquee-fund ownership over time
Nov 14, 2018Aug 13, 2021May 15, 2025May 15, 2026
Now
8
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2021 | 20Q | $61 | $57 | -6% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $77 | $57 | -26% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $57 | — |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $73 | $57 | -22% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $73 | $57 | -22% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $73 | $57 | -22% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $73 | $57 | -22% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management 2× in & out | Q4 2025 | Q2 2026 | — | +0% |
| Maverick Capital 4× in & out | Q2 2024 | Q3 2024 | → $73 | -24% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at HAEMONETICS CORP. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
9
Filings · last 90d
10
Total on file
598
Recent SEC buffer
Most recent
Jun 8, 2026
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40000313143-26-000068Jun 8, 2026
- Form 40000313143-26-000066Jun 8, 2026
- Form 40000313143-26-000048May 19, 2026
- Form 40000313143-26-000047May 19, 2026
- Form 40000313143-26-000046May 19, 2026
- Form 40000313143-26-000045May 19, 2026
- Form 40000313143-26-000044May 19, 2026
- Form 40000313143-26-000043May 19, 2026
- Form 40000313143-26-000042May 19, 2026
- Form 40000313143-26-000026May 5, 2026
- Form 40000313143-25-000078Nov 12, 2025
- Form 40000313143-25-000064Nov 3, 2025
- Form 40000313143-25-000061Sep 24, 2025
- Form 40001127602-25-019599Jul 25, 2025
- Form 40001127602-25-019598Jul 25, 2025
Showing 15 of 598 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · HAEMONETICS CORPORATIONAnnual figures sourced directly from HAEMONETICS CORPORATION's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$1.33B
FY2026-2% YoY
Net income
$97.31M
FY2026-42% YoY
EPS (diluted)
$2.05
FY2026-38% YoY
Free cash flow(?)
$260.44M
FY2026+83% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for HAEMONETICS CORP — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- DEF 14AProxy statementJun 9, 2026
- 8-KMaterial eventJun 5, 2026
- 10-KAnnual reportMay 20, 2026
- 8-KMaterial eventMay 7, 2026
- 8-KMaterial eventMay 1, 2026
- 8-KMaterial eventMar 3, 2026
- 8-KMaterial eventFeb 12, 2026
- 10-QQuarterly reportFeb 5, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KMaterial eventJan 9, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KMaterial eventJul 25, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2026 | open | $56 | $67 | +19% |
| Two Sigma Investments | Q2 2026 | open | $56 | $57 | +2% |
| Renaissance Technologies | Q2 2026 | open | $57 | $57 | +0% |
| D.E. Shaw | Q1 2026 | open | $59 | $57 | -2% |
| Millennium Management | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | $52 | $73 | +40% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Point72 Asset Management | Q2 2025 | open | $69 | $57 | -17% |
| D.E. Shaw | Q1 2025 | Q2 2025 | $62 | $69 | +11% |
| D.E. Shaw | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $73 | $57 | -22% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $73 | $69 | -5% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $73 | $91 | +24% |
| AQR Capital Management | Q3 2024 | open | $73 | $57 | -22% |
| Millennium Management | Q3 2024 | open | $73 | $57 | -22% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $73 | $91 | +24% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $77 | $62 | -19% |
| Maverick Capital | Q2 2024 | Q3 2024 | $96 | $73 | -24% |
| Bridgewater Associates | Q3 2021 | Q1 2026 | $61 | $58 | -6% |
| Maverick Capital | Q1 2020 | Q3 2020 | $121 | $84 | -30% |
| Maverick Capital | Q3 2019 | Q4 2019 | $135 | $120 | -11% |
| Maverick Capital | Q4 2018 | Q1 2019 | $106 | $86 | -19% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.